Compare HLIO & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLIO | PRCT |
|---|---|---|
| Founded | 1970 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | N/A | 2021 |
| Metric | HLIO | PRCT |
|---|---|---|
| Price | $59.28 | $34.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $52.40 | $51.13 |
| AVG Volume (30 Days) | 259.7K | ★ 1.3M |
| Earning Date | 02-23-2026 | 02-24-2026 |
| Dividend Yield | ★ 0.64% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.01 | N/A |
| Revenue | ★ $807,700,000.00 | $299,907,000.00 |
| Revenue This Year | $4.43 | $48.30 |
| Revenue Next Year | $1.03 | $29.44 |
| P/E Ratio | $55.69 | ★ N/A |
| Revenue Growth | N/A | ★ 50.07 |
| 52 Week Low | $24.76 | $27.80 |
| 52 Week High | $58.80 | $89.49 |
| Indicator | HLIO | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 66.37 | 56.79 |
| Support Level | $52.65 | $30.60 |
| Resistance Level | $56.85 | $32.94 |
| Average True Range (ATR) | 1.93 | 1.56 |
| MACD | 0.20 | -0.05 |
| Stochastic Oscillator | 97.11 | 66.92 |
Helios Technologies Inc is a industrial technology company that develops, manufactures, and markets solutions for the hydraulics and electronics markets. It operates under two business segments: Hydraulics and Electronics. The Hydraulics segment designs and manufactures hydraulic cartridge valves, hydraulic quick release couplings as well as engineers complete hydraulic systems. The Electronics segment designs and manufactures customized electronic controls systems and displays for a variety of end markets including industrial and mobile, recreational and health and wellness. It derives maximum revenue from the Hydraulics Segment.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.